Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis (NYSE: ANVS) will host a corporate update webinar with live Q&A on Wednesday, September 2, 2026, at 4:00 p.m. EDT, presented by Founder, President and CEO Maria Maccecchini, Ph.D.. The event will cover recent progress, clinical programs, and upcoming milestones for buntanetap in Alzheimer’s and Parkinson’s disease.
Annovis (NYSE: ANVS) reported second quarter 2026 results and clinical progress for buntanetap in Alzheimer’s and Parkinson’s disease. The pivotal Phase 3 early Alzheimer’s trial is now fully enrolled with 850 patients, above the original 760 target, with 6‑month top-line data expected in Q1 2027 and 18‑month data a year later.
An Alzheimer’s open‑label extension is planned to start in October 2026, while the Parkinson’s open‑label extension has enrolled 266 of a planned 500 patients across 26 US sites. Cash and equivalents were $18.7 million on June 30, 2026. Q2 research and development expenses rose to $12.0 million and general and administrative expenses to $2.4 million, driving a quarterly net loss of $14.8 million, or $0.40 per share. Annovis also promoted Cheng Fang, Ph.D., to Chief Scientific Officer and will host a corporate update webinar on September 2, 2026.
Annovis Bio (NYSE:ANVS) completed full enrollment in its pivotal Phase 3 trial of oral buntanetap for early Alzheimer’s disease, enrolling 850 pTau217-positive patients across 83 US sites.
The dual-design study targets 6‑month symptomatic and 18‑month disease‑modifying readouts, with top-line data expected in Q1 2027 and Q1 2028 and planned NDA submissions after each.
Annovis (NYSE: ANVS) promoted Cheng Fang, Ph.D., to Chief Scientific Officer. Fang, formerly Senior VP of R&D, will lead scientific strategy and research operations for the company’s Alzheimer’s and Parkinson’s programs.
The move comes as Annovis advances its oral therapy buntanetap toward Phase 3 Alzheimer’s top-line data and a potential NDA submission.
Annovis Bio (NYSE: ANVS) announced it has regained compliance with NYSE continued listing standards. The NYSE had notified the company on March 26, 2025 that its average global market cap and stockholders' equity were each below $50 million.
After NYSE accepted an 18‑month cure plan on June 19, 2025, Annovis executed corrective actions that raised both metrics above required thresholds within 12 months. NYSE has confirmed full compliance, and ANVS shares will remain listed as the company focuses on pivotal Phase 3 Alzheimer’s data and regulatory submissions.
Annovis (NYSE: ANVS) priced an underwritten public offering of 7,895,000 common shares and accompanying warrants to purchase up to 7,105,500 shares at a combined price of $1.90 per share and warrant.
Gross proceeds are expected to be about $15.0 million, mainly funding buntanetap Phase 3 programs in AD and PD.
Annovis (NYSE: ANVS) launched a proposed underwritten public offering of common stock and accompanying warrants, which must be purchased together. All securities are offered by the company, with Canaccord Genuity as sole bookrunner.
Net proceeds are expected to fund Phase 3 development of buntanetap for Alzheimer’s disease, plus working capital and general corporate purposes. The offering’s completion, size and terms remain subject to market and other conditions.
Annovis (NYSE: ANVS) reported first quarter 2026 updates on buntanetap for Alzheimer's and Parkinson's and its financial position.
The Phase 3 AD trial is 85% enrolled with positive 6‑month DSMB safety review, the PD OLE study is 40% enrolled, key publications and a new U.S. patent were issued, and cash totaled $14.2 million at March 31, 2026.
Annovis (NYSE: ANVS) announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, 2026 (1:40–2:05 PM, Picasso 4&5).
The talk covers a multi-protein model of Alzheimer’s disease, arguing for targeting amyloid, tau, alpha-synuclein, TDP-43 and other aggregating proteins. The presentation includes a Q&A and highlights Annovis’ lead oral drug, buntanetap, now in a pivotal Phase 3 trial.
Annovis (NYSE: ANVS) published Phase 2/3 results for oral buntanetap in Nature NPJ Dementia showing dose-dependent cognitive improvement in pTau217-positive mild AD patients and biomarker reductions. The randomized 12-week trial (351 patients) found buntanetap safe and well-tolerated, including in ApoE4 carriers. The company is advancing a pivotal Phase 3 in early AD (MMSE 20–28), now ~80% enrolled.
Biomarker changes included lower TDP-43, tau, NfL and reduced inflammatory markers, supporting potential disease-modifying activity; Phase 3 will evaluate effects at 6 and 18 months.